It is annoying to think that if Resverlogix had been better capitalized that BETonMACE could have been properly powered to meet the primary endpoint...or that the SSRA could have been done allowing the trial to be adjusted with more patients...again, meaning the need for more money.

The drug in the article is an injectible, and one would think that an oral drug like 208 would be much more attractive.   

Its all water under the bridge at this point, all the communication gaffes and missed opportunities....you can't go back and have a do-over.  Even if they'd been much more proactive and professional in their corporate communications there's no way to know if they would have succeeded in raising the money needed to properly fund a large Phase 3 trial instead of trying to squeak by with a smaller less expensive trial.

Thankfully MACE is just one apparent benefit.....maybe we'll be waiting for March after all for a big splash with eGFR numbers finally being published.  How they're financing operations in the here and now is still a big question....but however its being done, I don't think we're going to be getting any news on that front. 

It seems the company doesn't particularily care if prospective investors doing DD are presented with a company that does not appear to have the means to continue as a going concern....those of us who've been around for years however know Resverlogix is very adept at surviving when all fundamental indications point to a lack of survival.